Manufacturing business to drive Pharmaniaga’s growth

PETALING JAYA: Leading pharmaceutical player Pharmaniaga Bhd’s catalyst for growth will be its manufacturing business and projections of a higher revenue contribution from Indonesia, according to MIDF Research.

The research house has initiated a “buy” call with a target price of RM5.80, stating that apart from increased order from the Government and newly introduced generic drugs in the market, the manufacturing segment will be Pharmaniaga’s future earnings driver.